文献速递免疫规划卫生政策与健康促进

受控人类感染模型(CHIM)支持疫苗开发的美国监管考量

Use of controlled human infection models (CHIMs) to support vaccine development: US regulatory considerations.
PubMed 文献 · Vaccine · 2019-06-21

2016年美国FDA批准Vaxchora,其有效性主要证据来自人类挑战研究。本文讨论挑战接种物的化学制造与控制(CMC)、在美国IND下开展受控人类感染研究,以及利用CHIM支持疫苗开发的一般概念与监管考量。

要点

  • Vaxchora是首个主要有效性证据来自人类挑战研究的美国获批疫苗。
  • CHIM用于疫苗开发需关注挑战接种物的CMC及IND下安全开展。
  • 监管考量涵盖CHIM安全实施及评估疫苗有效性的应用。

核心结论

  • CHIM可用于支持安全有效疫苗的开发,但需遵循美国监管框架下的一般概念与考量。

研究设计与样本

  • 本文为监管考量论述,未报告系统检索或样本量。

主要发现

  • 2016年FDA批准Vaxchora用于成人抗O1血清群霍乱弧菌所致疾病的主动免疫。
  • Vaxchora是首个主要有效性证据来自人类挑战研究的美国获批疫苗。
  • FDA收到制造商、学术研究者、资助者等多方关于如何用CHIM支持疫苗开发的询问。

临床怎么用

  • 疫苗开发者可参考本文讨论的挑战接种物CMC、IND下CHIM开展及CHIM支持疫苗开发的监管考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2016, the United States (U.S.) Food and Drug Administration (FDA) licensed Vaxchora® for active immunization against disease caused by Vibrio cholerae serogroup 01 in adults. Vaxchora was the first US-licensed vaccine for which the primary evidence supporting effectiveness was derived from human challenge studies. Following this precedent, FDA has received numerous inquiries from manufacturers, academic researchers, funders and other stakeholders regarding how controlled human infection models (CHIMs) can be used to support the development of safe and effective vaccines to address public health needs. The aims of this article are to discuss: (1) Chemistry, Manufacturing and Controls (CMC) for challenge inocula, (2) conduct of controlled human infection studies under US IND and (3) use of CHIMs to support vaccine development. General concepts and regulatory considerations for the safe conduct of CHIMs and use of CHIMs to evaluate vaccine effectiveness are discussed.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ramanathan R, Stibitz S, Pratt D, et al. Use of controlled human infection models (CHIMs) to support vaccine development: US regulatory considerations. Vaccine. 2019. PMID: 31235375. doi:10.1016/j.vaccine.2019.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。